ErbB2 overexpression in mammary cells upregulates VEGF through the core promoter-Reference-Cited by-同舟云学术

ErbB2 overexpression in mammary cells upregulates VEGF through the core promoter

Published:2005-01 Issue:2 Volume:326 Page:455-465
ISSN:0006-291X
Container-title:Biochemical and Biophysical Research Communications
language:en
Short-container-title:Biochemical and Biophysical Research Communications

Author:

Loureiro Robyn M.B.,Maharaj Arindel S.R.,Dankort David,Muller William J.,D’Amore Patricia A.

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry,Biophysics

Reference63 articles.

1. Molecular and biological properties of the vascular endothelial growth factor family of proteins;Ferrara;Endocrine Rev.,1992

2. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele;Carmeliet;Nature,1996

3. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene;Ferrara;Nature,1996

4. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo;Kim;Nature,1993

5. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121;Asano;Cancer Res.,1995

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting HER2/VEGFR2 dual tyrosine kinases with novel Lapatinib and Neratinib hybrid analogues lead to potential apoptotic induction in HER2 positive breast cancers: Design, synthesis, in-vitro, in-vivo and molecular docking studies.;2023-08-22

2. Targeting Angiogenic Factors for the Treatment of Medulloblastoma;Current Treatment Options in Oncology;2022-04-12

3. HER2-Positive (HER2 +) Breast Cancer;Reference Module in Biomedical Sciences;2021

4. Phosphorylation of STAT3 and ERBB2 mediates hypoxia‑induced VEGF release in ARPE‑19 cells;Molecular Medicine Reports;2020-07-16

5. Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients;Frontiers in Oncology;2018-04-03